Tadalafil Tablet
Product Images NDC 31722-647

10 FDA label images from Camber Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 31722-647). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tasalafilstructure (Tadalafilstructure)

Tasalafilstructure (Tadalafilstructure)
Chemical structure of Tadalafil, showing its molecular skeleton including fused rings and functional groups characteristic of the compound.*
FDA Label Image

Tadalafilfigure1 (Tadalafilfigure1)

Tadalafilfigure1 (Tadalafilfigure1)
Line graph comparing mean change from baseline in meters over 16 weeks for Tadalafil 40 mg (N=76) versus placebo (N=82). The y-axis shows mean change from baseline in meters and the x-axis shows weeks. Tadalafil group shows a higher increase from baseline than placebo at weeks 4, 8, 12, and 16 with statistical significance indicated by p-values (0.0152, 0.0084, and 0.0004). Error bars display variability at each time point.*
FDA Label Image

Tadalafilfigure2 (Tadalafilfigure2)

Tadalafilfigure2 (Tadalafilfigure2)
A forest plot illustrating placebo-adjusted mean changes in 6-minute walk distance (meters) for Tadalafil 40 mg with 95% confidence intervals across multiple subgroups. The x-axis represents change in distance, ranging from -100 to 200 meters, while the y-axis lists subject characteristics like bosentan use, PAH etiology, baseline walking distance, gender, age, and WHO functional class. Each subgroup shows point estimates and confidence intervals for the drug effect.*
FDA Label Image

Tadalafilfigure3 (Tadalafilfigure3)

Tadalafilfigure3 (Tadalafilfigure3)
A Kaplan-Meier curve graph comparing percentage without clinical worsening over time (in days) for Tadalafil 40 mg, Tadalafil 20 mg, and placebo groups. The y-axis shows percentage without clinical worsening from 0 to 100%, and the x-axis shows time to clinical worsening in days from 0 to 150. The graph illustrates differences in clinical worsening rates among the three groups over the study period.*
FDA Label Image

Tadalafilfigure4 (Tadalafilfigure4)

Tadalafilfigure4 (Tadalafilfigure4)
A line chart displaying mean change from baseline (in meters) over a 16-week period, comparing Tadalafil 40 mg (N=79) to placebo (N=82). The x-axis represents weeks (0 to 16), and the y-axis shows mean change in meters, with Tadalafil showing steadily increasing improvement and placebo leveling off. Statistical significance markers are included.*
FDA Label Image

Tadalafilfigure5 (Tadalafilfigure5)

Tadalafilfigure5 (Tadalafilfigure5)
A forest plot chart showing the placebo-adjusted mean change in 6-minute walk distance (meters) for Tadalafil 40 mg versus placebo across various subject subgroups. The chart includes data points with 95% confidence intervals for groups based on bosentan use, PAH etiology, baseline 6-minute walk distance, gender, age, and WHO functional class. The horizontal axis ranges from -100 to 200 meters, illustrating changes in walking distance for each subgroup.*
FDA Label Image

Tadalafilfigure6 (Tadalafilfigure6)

Tadalafilfigure6 (Tadalafilfigure6)
A line graph showing percentage without clinical worsening over time in days for Tadalafil 20 mg, Tadalafil 40 mg, and placebo groups. The y-axis represents the percentage without clinical worsening, ranging from 0 to 100%, and the x-axis represents time to clinical worsening in days, from 0 to 150 days.*
FDA Label Image
FDA Label Image

Tadalafilcontainer30slabel (Tadalafilcontainer30slabel)

Tadalafilcontainer30slabel (Tadalafilcontainer30slabel)
Tadalafil 20 mg tablets packaging label from Camber Pharmaceuticals, Inc. The label displays the NDC 31722-647-30 and specifies oral tablets in a bottle of 30 count. It includes dosage information, storage instructions, and a barcode on the side. The label also notes manufacturing by Hetero Labs Limited, India.*
FDA Label Image

Tadalafilblistercartonlabel (Tadalafilblistercartonlabel)

Tadalafilblistercartonlabel (Tadalafilblistercartonlabel)
Packaging label for Tadalafil Tablets, USP 20 mg oral tablets by Camber Pharmaceuticals, Inc. The label indicates a unit-dose package of 100 tablets (10 x 10). The tablet is shown as oblong with imprint 'T15'. The label includes dosage storage instructions, manufacturer information, and a barcode. The product is Rx only and manufactured by Hetero Labs Limited, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.